Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx pediculicide

This article was originally published in The Tan Sheet

Executive Summary

Summers Laboratories is actively enrolling patients in a Phase III clinical trial for its patented lice asphyxiator product, tentatively named Lice Choker, the company announces April 24. An NDA for sale of the product as an Rx drug will be filed in the fourth quarter of 2006. The product contains "a simple mixture of ingredients currently used in other dermatological medications and cosmetics" and will suffocate lice more successfully than olive oil and petroleum jelly, Summers maintains. According to studies, two 10-minute applications of the product one week apart effectively kill all lice, the company states, with one study showing a 100% effective kill rate. A recent article in the Journal of the American Academy of Dermatology said asphyxiating treatments should be further researched, given the increasing resistance of lice to OTC pyrethroid-based formulas (1"The Tan Sheet" April 17, 2006, p. 13)...

Related Content

Topics

UsernamePublicRestriction

Register

PS099335

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel